August 10, 2021 + Jessica Di Palo
3 Minuten zu lesen
Investment led by MTIP enables the company to reduce the risk of clinical research, improve R&D productivity, and accelerate scientific breakthroughs through artificial intelligence (AI) and natural language processing (NLP).
MTIP is delighted to announce MTIP Fund II’s fourth investment in Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk. The closure of an oversubscribed $12M investment round was led by MTIP. Other investors include Big Pi Ventures, Synetro Group, as well as several of the company’s existing investors. ZS, a global professional services firm, has also participated in this round.
The company’s founders, Dimitrios Skaltsas and Vangelis Vergetis, met while at McKinsey & Company, and have spent more than a decade in the intersection of clinical development, data science, and technology solutions. Forbes recently included Intelligencia in their list of “America’s top 50 most promising AI companies”.
Intelligencia is an AI-driven technology company that focuses on minimizing the risk of drug development and enabling external innovation. It currently works with top-10 and mid-size global biopharmaceutical companies, smaller biotechs, prominent research centers, as well as investors in the biopharmaceutical space. With a focus on increasing R&D productivity, the company offers a suite of decision-making support solutions that enable its customers to minimize the risk of drug development, as well as streamline productivity and lower cost. Its platform allows customers to:
The company currently employs more than 40 people across the company’s headquarters in New York and the R&D center in Athens, Greece. The proceeds from this round will expand its R&D team in Athens, grow its sales and customer success teams in the US and in Europe, as well as allow it to work even more closely with customers and partners as they seek to incorporate their private/proprietary data into the company’s models.
“As we continue to aggressively expand Intelligencia’s business, we are privileged to have the support and guidance of industry veterans and company builders alike”, says Vangelis Vergetis. “Our aim has always been to make a difference when it comes to the incredibly risky business of drug development, and this funding round will allow us to continue to expand our product offering, our proprietary data, and our customer base.”
Danchen Zhao, who joins the Board of Directors on behalf of MTIP, said: «We see Intelligencia as an innovation leader in ML-based predictive analytics, offering actionable insights to life science organizations. We are impressed by their complementary team of data scientists, biologists and software engineers, that together continuously improve and expand their platform.» Dr. Christoph Kausch continued: «At MTIP, we see great potential in Artificial Intelligence and Machine Learning in the Life Science vertical. Intelligencia’s platform enables faster and more efficient drug development and helps to improve the success rate of novel therapies. This investment aligns with our philosophy of supporting innovation that enhances patients› quality of life and life expectations across therapeutic areas.”
“Increasingly, innovation in science and R&D requires technical expertise,” said Pratap Khedkar, CEO of ZS. “We are committed to supporting and partnering with innovative companies like Intelligencia to drive the adoption of next-generation technical capabilities – and robust data-driven decision making – for the biopharmaceutical industry.”
Dimitrios Skaltsas, talking about the team behind building a software product that is centered around specific customer needs, says: “Our fuel has been our unique knowledge graph, built on expertly curated data and ontologies. Equally, what has been crucial and much rewarding in our journey is bringing together a high-octane interdisciplinary team with both hard and soft skills, as well as constantly evolving with the direct input from our users at major organizations and cutting-edge biotech companies.”
For more information please contact:
Jessica Di Palo
Phone: +41 61 551 12 50
Intelligencia is an AI-driven technology company that focuses on minimizing the risk of drug development and enabling external innovation. It transforms how R&D and Business Development executives think about and assess the risk of clinical development programs and enables them to make more informed and data-driven decisions as they evaluate their own pipelines and/or external opportunities. Visit our website www.intelligencia.ai.
MTIP is a healthtech growth capital investor based in Basel, Switzerland. It invests in digital health and digitally-connected medical device companies, with offerings that provide clear health-related economic benefits. Its entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors. Visit www.mtip.ch to learn more.
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 10,000-plus ZSers in 28 offices worldwide, we are passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com.
Christoph Kausch selected by Real Deals as most influential for 2022
Christoph Kausch named by Real Deals most influential for 2022
MTIP leads €17 million financing round in virtual fertility clinic Apricity
New MTIP investment
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
MTIP schliesst zweiten Healthtech Growth Fonds mit $250 Millionen
MTIP schliesst zweiten Healthtech Fund
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
Dieser Text erscheint auf allen Übersichtsseiten (z.B. Story-Karussell)
MTIP invests in Mediktor
MTIP investiert in medizinischen Assistenten
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
MTIP invests in Oviva
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round